Chief Science Officer of Xhale subsidiary SMART Biotechnologies, Inc. elected an NAI Charter Fellow

The Chief Science Officer of the Xhale, Inc. subsidiary SMART Biotechnologies, Donn M. Dennis, M.D., F.A.H.A., has been elected a Charter Fellow by the National Academy of Inventors.

GAINESVILLE, FL – February 15, 2013

Xhale, Inc. announced today that the Chief Science Officer of their subsidiary, SMART Biotechnologies, Inc., has been elected by the National Academy of Inventors (NAI) as a Charter Fellow. Dr. Dennis is one of the 98 NAI elected academic innovators worldwide who has “demonstrated a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.”

Dr. Dennis is a co-founder of Xhale, Inc., a medical technology innovator headquartered in Gainesville, Florida. He is a board-certified anesthesiologist and previously served in various pharmaceutical company executive positions in the San Francisco area.

The 2012 Fellows elected by The National Academy of Inventors together hold more than 3,200 U.S. patents and were “nominated for outstanding contributions to innovation in areas such as patents and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation.” The Charter class includes eight Nobel Laureates, two Fellows of the Royal Society, 12 presidents of research universities and non-profit research institutes, 50 members of the National Academies (National Academy of Sciences, National Academy of Engineering, Institute of Medicine), 11 inductees of the National Inventors Hall of Fame, three recipients of the National Medal of Technology and Innovation, four recipients of the National Medal of Science, and 29 AAAS Fellows, among other major awards and distinctions.

As Chief Science Officer of Xhale and Xhale’s SMART Biotechnologies subsidiary, Dr. Dennis is leading the delivery of the SMART® Medication Adherence System to the medical market. This breakthrough technology measures, monitors, reports, and improves adherence to prescribed medication regimens. Dr. Dennis is a co-inventor on numerous patents, including patents underlying the SMART® System, the Assurance® patient monitoring system, and Xhale’s breath-based propofol monitoring and glucose monitoring technologies.

Dr. Dennis stated that he is “humbled to be named a member of this group,” and adds that, “My singular remaining career goal is to see the SMART® Adherence System become the de facto gold standard for measuring drug adherence in the majority of clinical trials and for optimizing disease management.”

In addition to his work with Xhale, Inc., Dr. Dennis is a professor in the Departments of Anesthesiology, Psychiatry and Pharmacology & Experimental Therapeutics in the College of Medicine at the University of Florida, where he holds the Joachim S. Gravenstein M.D. Endowed Chair in Anesthesiology and serves as Director of Nanomedicine. His career has focused on developing innovations in patient-centric medicine, particularly technologies to improve the safety and efficacy of drugs and to reduce the incidence of adverse events in medical settings.

The NAI Charter Fellows will be inducted by Margaret A. Focarino, the U.S. Commissioner for Patents from the United States Patent and Trademark Office (USPTO), during the 2nd Annual Conference of the National Academy of Inventors in Tampa, Florida on Feb. 22, 2013.

For more information on the NAI Fellows Program:

The 2012 NAI Charter Fellows are listed here:

For more Information on Donn M. Dennis, MD, FAHA

About SMART Biotechnologies

SMART Biotechnologies, a subsidiary of Xhale, has developed the SMART® Adherence System for the pharmaceutical industry, where it is being launched as a clinical trials tool for use in drug development. The breakthrough technology measures, monitors, reports, and improves adherence to prescribed medication regimens. The SMART® system is the only technology available that definitively verifies that the right person took the right dose of the right medication at the right time. The system is patient-centric and noninvasive. Utilizing exhaled breath, the SMART® system wirelessly reports – in real time – on medication adherence of participants in clinical trials, allowing immediate intervention when a participant misses a dose. SMART® technology is expected to have a direct impact on the success of drug approval, and help provide safer, more effective drug development.

About Xhale, Inc.

Xhale, Inc. is a medical technology innovator, developing products that transform healthcare and save lives. The company is a world leader in the use of sensors that analyze vapor and exhaled breath and is focused on novel patient-centric monitoring solutions. Its current product lines include SMART®, the world’s only definitive medication adherence monitoring system, and Assurance®, a replacement for conventional finger-based pulse oximetry which will monitor multiple patient parameters from a single-point-of-contact sensor, more comfortably and conveniently than finger-based pulse oximetry with fewer false alarms.


Download PDF: 2013-02-15 Donn Dennis NAI Fellowship